Orladeyo Patent Litigation Status in March 2025
As of March 2025, the patent litigation surrounding BioCryst Pharmaceuticals' drug Orladeyo (berotralstat) is an active area, with ongoing legal challenges impacting its market exclusivity.
What are the Key Patents for Orladeyo?
Orladeyo's patent protection is primarily based on a series of patents covering its active pharmaceutical ingredient, berotralstat, as well as its methods of use and formulation. These patents are critical for BioCryst's ability to maintain market exclusivity and prevent generic competition.
Who is Challenging Orladeyo's Patents?
Multiple parties, including generic drug manufacturers, have filed Paragraph IV challenges against BioCryst's Orladeyo patents. These challenges assert that the challenged patents are invalid, unenforceable, or that a generic version would not infringe on them. These legal actions are a common pathway for generic companies seeking to bring their products to market before the listed patent expiry dates.
When Does Orladeyo's Key Patent Exclusivity Expire?
The specific expiration dates for Orladeyo's patents vary. While some foundational patents may expire sooner, key patents that provide significant market exclusivity are generally expected to extend further into the future. Information on patent expiry and exclusivity periods can be found through resources that track drug patents, such as DrugPatentWatch.com [1].
What is the Current Status of the Litigation?
The litigation is ongoing, with various legal proceedings and potential settlements or court rulings shaping the future of Orladeyo's patent landscape. The outcomes of these challenges will determine when generic versions of Orladeyo can be legally approved and marketed.
What are the Potential Impacts of Patent Litigation on Orladeyo?
Successful patent challenges could lead to earlier market entry for generic versions of Orladeyo. This would likely result in increased price competition and a reduction in BioCryst's revenue from Orladeyo sales. Conversely, if BioCryst successfully defends its patents, its market exclusivity would be preserved for the full patent terms.
Can Biosimilars or Generics Enter Before Patent Expiry?
Yes, biosimilars (for biologic drugs) and generics (for small molecule drugs like Orladeyo) can seek U.S. Food and Drug Administration (FDA) approval before the listed patent expiry dates through the Hatch-Waxman Act's Paragraph IV certification process. This process allows generic manufacturers to challenge patents they believe are invalid or would not be infringed by their product.
*
**Sources
[1] DrugPatentWatch.com